CYP2C19型
CYP2C9
苯妥英钠
药代动力学
药理学
医学
内科学
科克伦图书馆
CYP3A4型
胃肠病学
荟萃分析
细胞色素P450
新陈代谢
癫痫
精神科
作者
Juntip Kanjanasilp,Ratree Sawangjit,Sirikhwan Phanthaisong,Wongvaruth Borihanthanawuth
出处
期刊:Pharmacogenomics
[Future Medicine]
日期:2021-07-01
卷期号:22 (10): 629-640
被引量:6
标识
DOI:10.2217/pgs-2020-0151
摘要
Aim: Phenytoin is metabolized through CYP2C9 and CYP2C19 . Polymorphisms of CYP2C9 and CYP2C19 may increase plasma concentration and side effects. Materials & methods: Systematic review and meta-analysis were performed to evaluate the effects of CYP2C9 and CYP2C19 polymorphism on pharmacokinetic parameters. PubMed, Science Direct, Cochrane library, and Thai databases were systematically searched. Results: Eight observational studies, comprising a total of 633 patients were included. Michaelis–Menten constant was significantly higher in the polymorphism of CYP2C9IM/CYP2C19EM and CYP2C9IM/CYP2C19IM groups as compared with the control groups (CYP2C9EM/CYP2C19EM) at 2.16 and 1.55 mg/l (p < 0.00001, p < 0.0001). The maximum rate of action was significantly lower in the control groups as compared with the polymorphism of CYP2C9IM/CYP2C19EM and CYP2C9IM/CYP2C19IM groups at 3.10 and 3.53 mg/kg/day (p = 0.00001, <0.0001). Conclusion: The dosage regimen for patients in the CYP2C9IM group to achieve phenytoin therapeutic levels was 2.1–3.4 mg/kg/day.
科研通智能强力驱动
Strongly Powered by AbleSci AI